Can adding a targeted pill to chemo beat resistant lung cancer?
NCT ID NCT04765059
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This Phase 3 trial tests whether adding the targeted drug osimertinib to standard chemotherapy can help people with advanced EGFR-mutant non-small cell lung cancer whose disease has progressed after initial osimertinib treatment. About 98 participants will receive either osimertinib plus chemo or a placebo plus chemo. The main goal is to see if the combination delays cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Osimertinib (a targeted cancer pill) combined with chemotherapy (pemetrexed plus cisplatin or carboplatin)
- What this could lead to
- If successful, this could offer a new treatment option for people with EGFR-mutant lung cancer whose disease has worsened after initial osimertinib therapy.
- What could go wrong
- This is a relatively small Phase 3 trial (98 participants) and results may not apply to all patients. Adding osimertinib to chemo may increase side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Silver Spring, Maryland, 20910, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Beijing, 100005, China
-
Research Site
Beijing, 100142, China
-
Research Site
Ganzhou, 341099, China
-
Research Site
Guangzhou, 510080, China
-
Research Site
Jinan, 250013, China
-
Research Site
Shenyang, 110001, China
-
Research Site
Tianjin, 300060, China
-
Research Site
Zhengzhou, 450008, China
-
Research Site
Berlin, 12351, Germany
-
Research Site
Cologne, 50937, Germany
-
Research Site
Cologne, 51109, Germany
-
Research Site
Hanover, 30625, Germany
-
Research Site
München, D-80336, Germany
-
Research Site
Beersheba, 84101, Israel
-
Research Site
Jerusalem, 9103102, Israel
-
Research Site
Jerusalem, 9112001, Israel
-
Research Site
Kfar Saba, 4428164, Israel
-
Research Site
Tel Aviv, 6423906, Israel
-
Research Site
Tel Litwinsky, 52621, Israel
-
Research Site
Florence, 50134, Italy
-
Research Site
Meldola, 47014, Italy
-
Research Site
Messina, 98158, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Padova, 35128, Italy
-
Research Site
Roma, 00168, Italy
-
Research Site
Terni, 05100, Italy
-
Research Site
Verona, 37124, Italy
-
Research Site
Alicante, 03010, Spain
-
Research Site
Barcelona, 08907, Spain
-
Research Site
Córdoba, 14004, Spain
-
Research Site
León, 24071, Spain
-
Research Site
Madrid, 28040, Spain
-
Research Site
Málaga, 29010, Spain
-
Research Site
Murcia, 30008, Spain
-
Research Site
Oviedo, 33011, Spain
-
Research Site
Palma de Mallorca, 07010, Spain
-
Research Site
Seville, 41013, Spain
-
Research Site
Valencia, 46010, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?